SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of excitement and skepticism around its recent surge, with community members debating whether it's a legitimate rise or a potential bubble. The stock's connection to the quantum computing sector and AI, coupled with discussions about its valuation and revenue, are fueling the conversations. Some traders are pointing to potential short squeezes, while others are wary of a significant pullback.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid high trading volume and community excitement, with some investors anticipating significant catalysts in the near future, possibly driven by speculation around new partnerships. Community members are pointing to the high short interest, hinting at a potential squeeze, while also highlighting the company's potential for growth in the eVTOL sector.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors celebrate the stock finally breaking the $40 mark, a level many have been watching for a long time, driven by expansion news. The community is expressing bullish sentiment, anticipating further growth and a potential Nasdaq relisting. Overall, the mood is optimistic as traders reflect on the company's journey and future potential.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate the implications of its AI spending and recent moves into private debt markets, drawing comparisons to pre-2008 financial tactics. Community discussion revolves around the stock's volatility and whether its pullback represents a buying opportunity or reflects deeper concerns about AI investments. Some are pointing to potential data center deals as a possible catalyst.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending as investors react to news of $IMG pulling its S-1 filing, eliminating concerns about potential dilution. The community is also buzzing about ANRO's expansion into crypto AI, including a $55M Bitcoin deal and a $20M fund with iZUMi. Bullish sentiment seems to be building amidst discussions of potential breakouts and short squeezes.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision, encapsulated by the phrase "Like Bitcoin But Way Higher". Active discussions involve the project's roadmap and potential, with community members emphasizing its cultural relevance and potential for growth, particularly regarding developments in the broader cannabis industry.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble ($RUM) is trending due to its strategic partnership with Perplexity AI, sparking discussions about enhanced content discovery and potential synergies within the AI space. The community is actively debating the impact of this partnership, especially given Rumble's existing ties to crypto through Tether and its potential to become a major cloud provider. High short interest is adding fuel to the fire, with many anticipating a significant short squeeze.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending with significant volume, fueled by community excitement and talk of a potential surge to new highs. Investors are actively discussing the company's potential to reach mid-cap status and the anticipation of news in October, while some reference a past short report as a catalyst for the stock's recent momentum. Discussion also includes comparisons to other robotics companies and speculation around the impact of robotics on the future.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as the community debates the impact of potential regulatory challenges related to compounded drugs. Some traders are capitalizing on volatility with options strategies, while others express concern over insider selling and the company's business practices. Despite differing opinions, many bulls believe HIMS is poised for significant growth and a potential short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ISRG Expands SP Indications: A Game Changer in Colorectal Surgery?

Intuitive Surgical's SP platform secures new colorectal clearances, with 88% growth in procedures and rising global adoption momentum.

Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE? 

ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.

Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?

Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.

AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?

AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.

Johnson & Johnson (JNJ) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Should You Invest in Johnson & Johnson (JNJ) Based on Bullish Wall Street Views?

Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures

SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.

U.S. President Donald Trump’s caution against Tylenol has reignited scrutiny of Kenvue, just as the U.S. FDA moves to add pregnancy-related autism warnings to acetaminophen labels and has alerted physicians nationwide.&nbsp;Although the agency acknowledged that no causal link has been established, plaintiffs’ lawyers say the new language could revive litigation dismissed by a federal court last December, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-23/tylenol-maker-kenvue-faces-mounting-crisis-after-trump-s-rebuke">report</a>.&nbsp;The heightened risk comes as Kenvue, under interim CEO Kirk Perry, faces weak sales, activist investor demands, and a portfolio review. Tylenol, its largest brand, contributes a mid- to high-single-digit share of revenue.&nbsp;Despite the legal overhang, Kenvue’s stock shrugged off concerns, rising 1.6% in regular trade and another 0.8% after hours on Tuesday. Investors took comfort in the fact that the FDA stopped short of a ban and that no new scientific evidence was presented.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-kenvue-stock-rising-today/chDhDbOR350">Citigroup said it sees limited legal risk</a> and expects shares to trade higher, while Evercore ISI cut its price target to $18. Barclays argued that the recent selloff looks overdone, even under highly unlikely worst-case scenarios.The move may also mark Kenvue’s biggest reputational test since the 1980s Tylenol cyanide poisonings, with concerns&nbsp;that it could create confusion for patients who need to treat fevers during pregnancy.Plaintiffs’ lawyer Mark Lanier said the FDA move breathes new life into lawsuits, while legal experts noted courts rarely overturn the agency’s risk assessments. Kenvue stated that the claims lack both legal and scientific merit. Johns Hopkins professor Stacey Lee said even without proving causality, the label could be powerful evidence before juries.The company has been unsettled since its 2023 spin-off from Johnson &amp; Johnson. Former CEO Thibaut Mongon struggled to stabilize operations, prompting pressure from activist hedge funds Starboard Value, TOMS Capital, and Third Point. Kenvue responded by naming Perry interim CEO, adding Starboard’s Jeffrey Smith to its board, and&nbsp;considering the sale&nbsp;of smaller skincare brands, such as Neutrogena.The business faces a&nbsp;challenging consumer backdrop of inflation, high interest rates, and weaker demand, which has led to two consecutive quarters of declining organic sales and a reduction to its full-year forecast.&nbsp;On Stocktwits, retail sentiment for Kenvue was ‘bullish’ amid a 270% surge in 24-hour message volume.One user pointed out that no direct causal link between pregnancy and autism has been established and described the stock as a “huge buying opportunity,” adding that they bought shares after hours and expect it to soon reach $21.<stembedurl>https://stocktwits.com/Mukulu2025/message/629750922</stembedurl>Another bullish user called Kenvue a “great investment opportunity.”<stembedurl>https://stocktwits.com/Little_thebodyguard/message/629750599</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tylenol, which contains acetaminophen, is offered for sale at a drug store on April 14, 2015 in Chicago, Illinois. (Photo by Scott Olson/Getty Images)

Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’

Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry.

Equity

Shares of Johnson &amp; Johnson held up better than its consumer spinoff, Kenvue, on Monday after U.S. President Donald Trump linked autism to Tylenol and childhood vaccines, claims that decades of scientific research have not supported.&nbsp;J&amp;J shares slipped 1.1% to $174.21 in regular trade before gaining 0.5% after hours. Meanwhile, Kenvue fell 7.5% to a record low at $16.97 before rebounding 4.4% in late trading.&nbsp;Guggenheim upgraded J&amp;J to ‘Buy’ from ‘Neutral’ with a raised price target of $206 from $167, which implies an upside of 18% from J&amp;J’s closing price on Monday.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kenvue-stock-hits-record-low-trump-urges-pregnant-women-fight-like-hell-against-tyleno/chDhg0tR3PR">Trump’s sharp warnings against acetaminophen</a>, the active ingredient in Tylenol, directly pressured Kenvue, while J&amp;J moved lower more modestly, supported by its diversified portfolio and pipeline updates.Johnson &amp; Johnson has also remained a defensive play for income investors. The company went ex-dividend on Aug. 26, with its most recent quarterly payout made on Sept. 9, underscoring its steady record of shareholder returns even as sector peers face volatility.Earlier this month, Josh Brown, CEO of Ritholtz Wealth Management, told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/09/16/josh-browns-best-stocks-in-the-market-johnson-johnson.html">CNBC</a> that J&amp;J’s transformation into a pure-play healthcare company after spinning off Kenvue, coupled with a pipeline focused on oncology, immunology, neuroscience, and medtech, is helping steady sentiment. He noted the stock has been “building a base” for years and could be on the verge of a breakout if it clears long-term resistance.The company also drew attention in the U.S. Psychiatric and Mental Health Congress, where it released Phase 3 data for its investigational depression treatment seltorexant on Monday. The trial showed the drug has efficacy similar to that of quetiapine XR, a frequently used adjunctive therapy, but was well-tolerated with&nbsp;fewer adverse events like drowsiness and weight gain.&nbsp;While it did not hit its primary target, seltorexant was still better tolerated as measured by a higher completion rate at week 26, supporting its use in patients with major depressive disorder who are still suffering from insomnia symptoms.On Friday, J&amp;J also said the FDA approved a subcutaneous induction regimen of Tremfya for adults with ulcerative colitis, making it the first IL-23 inhibitor to offer both SC and IV induction options for UC and Crohn’s disease, which&nbsp;affects about 3 million Americans.&nbsp;On Stocktwits, retail sentiment&nbsp;for JNJ,&nbsp;however, was ‘extremely bearish’ amid&nbsp;a 1,720% spike in 24-hour message volume. One user said J&amp;J could still face billions in liability from Tylenol autism suits despite Kenvue assuming primary responsibility after the 2023 spin-off, especially when combined with ongoing talc cases.&nbsp;<stembedurl>https://stocktwits.com/StormChaser/message/629585491</stembedurl>Another&nbsp;user jokingly remarked that with more than 66,000 talc plaintiffs and fresh Tylenol claims, J&amp;J might soon “own the largest law firm in the world.”<stembedurl>https://stocktwits.com/Suite510/message/629583920</stembedurl><a href="https://stocktwits.com/symbol/JNJ">Johnson &amp; Johnson’s stock</a> has risen 23.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Johnson and Johnson American multinational of medical, pharmaceutical and perfumery products headquartes on 28 January 2025 in Madrid, Spain.

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check?

Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$188.74
Prev Close	$185.98
Open	$187.72
Dividend Yield	3.40%
50-Day Moving Average	$175.65
Beta	0.15
Avg. Volume	8.61M
PE Ratio	19.89

52-Week High	$186.59
52-Week Low	$140.68
Market Capitalization	$447.9B
EPS (Annual)	$5.79
Price to Book	5.70
Revenue Per Employee	$635,329.04
Enterprise Value/EBITDA	N/A

JNJ
Johnson & Johnson

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JNJ News

JNJ Johnson & Johnson